Get started
Author

Hideaki Suna

Observed name: H SUNA
ORCID: 0000-0001-9202-316X
Observed ORCID: 0000-0001-9202-316X
OpenAlex ID: A5084823254
A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors
2019 · Toshihiko Doi, Kei Muro, et al. · Clinical Cancer Research · 156
Structure–activity relationship and biological property of cortistatins, anti-angiogenic spongean steroidal alkaloids
2007 · Shunji Aoki, Yasuo Watanabe, et al. · Bioorganic & Medicinal Chemistry · 99
Aaptamine, a spongean alkaloid, activates p21 promoter in a p53-independent manner
2006 · Shunji Aoki, Dexin Kong, et al. · Biochemical and Biophysical Research Communications · 63
Elevation of serum acid phosphatase in Gaucher's disease.
1956 · L R TUCHMAN, H SUNA, et al. · PubMed · 53
A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer
2022 · Hirotaka Hasegawa, Kohei Shitara, et al. · Gastric Cancer · 39
PDF
Dysideamine, a new sesquiterpene aminoquinone, protects hippocampal neuronal cells against iodoacetic acid-induced cell death
2009 · Hideaki Suna, Masayoshi Arai, et al. · Bioorganic & Medicinal Chemistry · 34
Phase I Studies of Peptide Vaccine Cocktails Derived from GPC3, WDRPUH and NEIL3 for Advanced Hepatocellular Carcinoma
2021 · Masafumi Ikeda, Takuji Okusaka, et al. · Immunotherapy · 30
Crambescidin 800, a pentacyclic guanidine alkaloid, protects a mouse hippocampal cell line against glutamate-induced oxidative stress
2007 · Hideaki Suna, Shunji Aoki, et al. · Journal of Natural Medicines · 27
Anti-stress effects of ONO-2952, a novel translocator protein 18 kDa antagonist, in rats
2015 · Katsukuni Mitsui, Tomohiro Niwa, et al. · Neuropharmacology · 22
Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
2025 · Kohei Shitara, Motohiro Tamiya, et al. · Cancer Research Communications · 2
PDF
Imidafenacin, An Orally Active Muscarinic Receptor Antagonist, Improves Pulmonary Function In Patients With Chronic Obstructive Pulmonary Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled 3×3 Crossover Phase II Trial
2019 · Kentaro Machida, Tomotaka Kawayama, et al. · International Journal of COPD · 1
PDF
Supplementary Table S2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
2025 · Kohei Shitara, Motohiro Tamiya, et al.
Supplementary Table S3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
2025 · Kohei Shitara, Motohiro Tamiya, et al.
Supplementary Table S1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
2025 · Kohei Shitara, Motohiro Tamiya, et al.
Supplementary Table S1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
2025 · Kohei Shitara, Motohiro Tamiya, et al.
Supplementary Table S2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
2025 · Kohei Shitara, Motohiro Tamiya, et al.
Supplementary Table S3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
2025 · Kohei Shitara, Motohiro Tamiya, et al.
Supplementary Table S3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
2025 · Kohei Shitara, Motohiro Tamiya, et al.
Table 4 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
2025 · Kohei Shitara, Motohiro Tamiya, et al.
Table 2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
2025 · Kohei Shitara, Motohiro Tamiya, et al.
Figure 2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
2025 · Kohei Shitara, Motohiro Tamiya, et al.
Table 3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
2025 · Kohei Shitara, Motohiro Tamiya, et al.
Supplementary Table S1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
2025 · Kohei Shitara, Motohiro Tamiya, et al.
Supplementary Table S2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
2025 · Kohei Shitara, Motohiro Tamiya, et al.
Figure 1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
2025 · Kohei Shitara, Motohiro Tamiya, et al.
Works count: 33
Citation count: 526
H-index: 9
I10-index: 9
Year
Topic
Type